101 related articles for article (PubMed ID: 22343424)
1. Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/- mice.
Freeland MM; Angulo J; Davis AL; Flook AM; Garcia BL; King NA; Mangibin SK; Paul KM; Prosser ME; Sata N; Bentley JL; Olson LE
Anticancer Drugs; 2012 Jul; 23(6):584-9. PubMed ID: 22343424
[TBL] [Abstract][Full Text] [Related]
2. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.
Olson LE; Bedja D; Alvey SJ; Cardounel AJ; Gabrielson KL; Reeves RH
Cancer Res; 2003 Oct; 63(20):6602-6. PubMed ID: 14583452
[TBL] [Abstract][Full Text] [Related]
3. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS
Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096
[TBL] [Abstract][Full Text] [Related]
5. Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.
Breysse DH; Boone RM; Long CM; Merrill ME; Schaupp CM; White CC; Kavanagh TJ; Schmidt EE; Merrill GF
Drug Metab Dispos; 2020 Mar; 48(3):187-197. PubMed ID: 31955137
[TBL] [Abstract][Full Text] [Related]
6. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
[TBL] [Abstract][Full Text] [Related]
7. Up-Regulation of Carbonyl Reductase 1 Renders Development of Doxorubicin Resistance in Human Gastrointestinal Cancers.
Matsunaga T; Kezuka C; Morikawa Y; Suzuki A; Endo S; Iguchi K; Miura T; Nishinaka T; Terada T; El-Kabbani O; Hara A; Ikari A
Biol Pharm Bull; 2015; 38(9):1309-19. PubMed ID: 26328486
[TBL] [Abstract][Full Text] [Related]
8. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
9. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.
Tak E; Lee S; Lee J; Rashid MA; Kim YW; Park JH; Park WS; Shokat KM; Ha J; Kim SS
J Hepatol; 2011 Feb; 54(2):328-39. PubMed ID: 21056497
[TBL] [Abstract][Full Text] [Related]
10. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
Fan L; Goh BC; Wong CI; Sukri N; Lim SE; Tan SH; Guo JY; Lim R; Yap HL; Khoo YM; Iau P; Lee HS; Lee SC
Pharmacogenet Genomics; 2008 Jul; 18(7):621-31. PubMed ID: 18551042
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism.
Zhou F; Hao G; Zhang J; Zheng Y; Wu X; Hao K; Niu F; Luo D; Sun Y; Wu L; Ye W; Wang G
Br J Pharmacol; 2015 Dec; 172(23):5690-703. PubMed ID: 25363561
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.
Schaupp CM; White CC; Merrill GF; Kavanagh TJ
Chem Biol Interact; 2015 Jun; 234():154-61. PubMed ID: 25446851
[TBL] [Abstract][Full Text] [Related]
13. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Lal S; Sandanaraj E; Wong ZW; Ang PC; Wong NS; Lee EJ; Chowbay B
Cancer Sci; 2008 Oct; 99(10):2045-54. PubMed ID: 19016765
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1.
Miura T; Nagai K; Kaneshiro S; Taketomi A; Nakabayashi T; Konishi H; Nishinaka T; Terada T
Drug Metab Lett; 2017 Nov; 11(1):48-52. PubMed ID: 28332451
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol reduces the hypoxia-induced resistance to doxorubicin in breast cancer cells.
Mitani T; Ito Y; Harada N; Nakano Y; Inui H; Ashida H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(2):122-8. PubMed ID: 24975222
[TBL] [Abstract][Full Text] [Related]
16. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
Salvatorelli E; Menna P; Paz OG; Chello M; Covino E; Singer JW; Minotti G
J Pharmacol Exp Ther; 2013 Feb; 344(2):467-78. PubMed ID: 23192654
[TBL] [Abstract][Full Text] [Related]
17. Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma.
Huang W; Ding L; Huang Q; Hu H; Liu S; Yang X; Hu X; Dang Y; Shen S; Li J; Ji X; Jiang S; Liu JO; Yu L
Hepatology; 2010 Aug; 52(2):703-14. PubMed ID: 20683966
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.
Ferguson DC; Cheng Q; Blanco JG
Drug Metab Dispos; 2015 Jul; 43(7):922-7. PubMed ID: 25918240
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).
Gonzalez-Covarrubias V; Kalabus JL; Blanco JG
Pharm Res; 2008 Jul; 25(7):1730-4. PubMed ID: 18449627
[TBL] [Abstract][Full Text] [Related]
20. Identification of carbonyl reductase 1 as a resveratrol-binding protein by affinity chromatography using 4'-amino-3,5-dihydroxy-trans-stilbene.
Ito Y; Mitani T; Harada N; Isayama A; Tanimori S; Takenaka S; Nakano Y; Inui H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2013; 59(4):358-64. PubMed ID: 24064738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
